Turnover of exogenous artificial surfactant
- PMID: 1586175
- PMCID: PMC1590490
- DOI: 10.1136/adc.67.4_spec_no.383
Turnover of exogenous artificial surfactant
Abstract
The turnover of the artificial surfactant Exosurf after its administration to infants with respiratory distress syndrome was studied. High performance liquid chromatography was used to compare the phosphatidylcholine (PC) composition of serial endotracheal tube secretions from three groups of infants. There were 22 infants who received two doses of Exosurf in 24 hours (group 1), 10 infants who received four doses in 36 hours (group 2), and 41 control infants who did not receive Exosurf. Two parameters were studied: (i) dipalmitoylphosphatidylcholine (DPPC), which is present in both Exosurf and endogenous surfactant, expressed as a percentage of total PC (% DPPC) and (ii) the ratio of DPPC to the entirely endogenous palmitoyloleoylphosphatidylcholine (DPPC:POPC ratio). The administration of Exosurf produced changes in endotracheal tube aspirate PC composition that were detectable for over one week. Four doses of Exosurf in 36 hours prolonged the persistence of these changes compared with two doses in 24 hours, but the numbers of infants were small, and should not be over-interpreted. We conclude that after giving two doses of Exosurf, further doses might best be delayed until after two days, and that further clinical evaluation of dosage regimens is required.
Similar articles
-
Phosphatidylcholine composition of endotracheal tube aspirates of neonates and subsequent respiratory disease.Arch Dis Child. 1992 Apr;67(4 Spec No):378-82. doi: 10.1136/adc.67.4_spec_no.378. Arch Dis Child. 1992. PMID: 1586174 Free PMC article.
-
Susceptibility of exogenous surfactant to phospholipase A2 degradation.Can J Physiol Pharmacol. 1996 Aug;74(8):957-63. Can J Physiol Pharmacol. 1996. PMID: 8960386
-
A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.N Engl J Med. 1991 Dec 12;325(24):1696-703. doi: 10.1056/NEJM199112123252404. N Engl J Med. 1991. PMID: 1944470 Clinical Trial.
-
Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.Drugs. 1991 Nov;42(5):877-94. doi: 10.2165/00003495-199142050-00009. Drugs. 1991. PMID: 1723378 Review.
-
Exogenous surfactant use in neonates.Ann Pharmacother. 1996 Apr;30(4):389-98. doi: 10.1177/106002809603000412. Ann Pharmacother. 1996. PMID: 8729894 Review.
Cited by
-
Metabolism of a synthetic compared with a natural therapeutic pulmonary surfactant in adult mice.J Lipid Res. 2018 Oct;59(10):1880-1892. doi: 10.1194/jlr.M085431. Epub 2018 Aug 14. J Lipid Res. 2018. PMID: 30108154 Free PMC article.
-
The fate of exogenous surfactant in neonates with respiratory distress syndrome.Clin Pharmacokinet. 1994 Mar;26(3):215-32. doi: 10.2165/00003088-199426030-00005. Clin Pharmacokinet. 1994. PMID: 8194284 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources